PCL, Inc. (KOSDAQ: 241820)

Market Cap	70.73B
Revenue (ttm)	7.83B
Net Income (ttm)	-15.12B
Shares Out	56.68M
EPS (ttm)	-245.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	219,639
Open	1,272.00
Previous Close	1,266.00
Day's Range	1,221.00 - 1,291.00
52-Week Range	949.00 - 4,725.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 241820

Financial Performance

In 2023, PCL, Inc.'s revenue was 8.43 billion, a decrease of -77.35% compared to the previous year's 37.22 billion. Losses were -20.32 billion, 405.7% more than in 2022.